Page last updated: 2024-08-21

thiazoles and byl719

thiazoles has been researched along with byl719 in 168 studies

Research

Studies (168)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	83 (49.40)	24.3611
2020's	85 (50.60)	2.80

Authors

Authors	Studies
Aichholz, R; Blanz, J; Blasco, F; Bruce, I; Caravatti, G; Fabbro, D; Fairhurst, RA; Fritsch, C; Furet, P; Guagnano, V; Hamon, J; Imbach-Weese, P; Knapp, M	1
Ambrosini, G; de Stanchina, E; Musi, E; Schwartz, GK	1
Boehm, M; Brachmann, SM; Caravatti, G; Chatenay-Rivauday, C; Chene, P; Cozens, R; De Pover, A; Erdmann, D; Ferretti, S; Fritsch, C; Furet, P; Gao, H; Garcia-Echeverria, C; Guthy, D; Hofmann, F; Huang, A; Kauffmann, A; Lehar, J; Liu, M; Maira, SM; Reddy, A; Schlegel, R; Schnell, C; Sellers, WR; Trappe, J; Wang, Y; Wiesmann, M; Wilson, C	1
Boehm, M; Bootle, D; De Buck, SS; Goggin, TK; Jakab, A; Juric, D; Quadt, C	1
Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y	1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A	1
Battaglia, S; Blanchard, F; Charrier, C; Gobin, B; Heymann, D; Huin, MB; Lamoureux, F; Lanel, R; Lezot, F; Ory, B; Redini, F	1
Ahn, JS; Ahn, MJ; Bae, YH; Jho, EH; Ku, BM; Park, K; Sun, JM	1
Ainscough, BJ; Baselga, J; Berger, MF; Castel, P; Derti, A; Ebbesen, SH; Elamine, L; Ellis, H; Griffith, M; Griffith, OL; Huang, A; Huynh, T; Isakoff, S; Iyer, G; Juric, D; Lowe, SW; Mardis, ER; Mino-Kenudson, M; Peters, M; Quadt, C; Ramu, A; Scaltriti, M; Schegel, R; Sgroi, D; Shah, RH; Solit, DB; Thabet, A; Won, HH	1
Deuker, MM; Marsh Durban, V; McMahon, M; Phillips, WA	1
Barry, ST; Baselga, J; Carver, BS; Chandarlapaty, S; de Stanchina, E; Hancox, U; Rodrik-Outmezguine, V; Rosen, N; Sawyers, CL; Scher, HI; Schwartz, S; Trigwell, CB; Will, M; Wongvipat, J; Yellen, P	1
Beausoleil, SA; Benes, CH; Costa, C; Ebi, H; Engelman, JA; Faber, AC; Hall, B; Hirsch, E; Huang, A; Jakubik, CT; Martini, M; Nishtala, M; Rikova, K; Wang, Y; Zhao, J	1
Ahn, YO; Heo, DS; Keam, B; Kim, DW; Kim, S; Kim, TM; Lee, SH	1
Cescon, DW; Gorrini, C; Mak, TW	1
Altman, JK; Beauchamp, EM; Bliss-Moreau, M; Blyth, G; Colamonici, M; Giles, FJ; Platanias, LC; Saleiro, D; Szilard, A	1
Baselga, J; Benzaken, AO; Bivona, TG; Brook, S; Chen, Y; Das, R; Elkabets, M; Ghossein, RA; Gurski, JM; Huang, A; Juric, D; Kerr, DA; Liang, J; Liu, M; Morse, N; Pazarentzos, E; Pelossof, RA; Rodon, J; Rosell, R; Rosen, N; Scaltriti, M; Sheng, Q; Tam, A; Teixidó, C; Wang, H; Yan, JJ	1
Baselga, J; Bergamaschi, A; Bosch, A; Castel, P; Chandarlapaty, S; Cortes, J; Dickler, M; Ellis, H; Galvan, P; Grueso, J; Guzman, M; Ibrahim, Y; Katzenellenbogen, JA; Kharas, M; Lewis, JS; Li, Z; Minuesa, G; Morse, N; Perez-Garcia, J; Prat, A; Rodón, J; Rosen, N; Scaltriti, M; Serra, V; Spratt, DE; Tao, JJ; Toska, E; Viola-Villegas, NT	1
Alfieri, RR; Ardizzoni, A; Bonelli, MA; Caffarra, C; Cavazzoni, A; Cretella, D; Falco, A; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, CA; Madeddu, D; Petronini, PG; Quaini, F; Rossetti, P; Saccani, F; Tiseo, M	1
Blumenstein, L; Demailly, A; Glaenzel, U; Hansen, R; Hazell, K; Jakab, A; James, A; Jin, Y; Mehta, A; Swart, P; Trandafir, L	1
Krop, IE; Lin, NU; Liu, P; Roberts, TM; Spangle, JM; Von, T; Wang, Q; Winer, EP; Zhao, JJ	1
Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ	1
Boon, LM; Eklund, L; Godfraind, C; Helaers, R; Kangas, J; Limaye, N; Mendola, A; Schlögel, MJ; Vikkula, M	1
Fawzi, AA; Gill, MK; Scarinci, F; Sheyman, AT	1
Bentires-Alj, M; Bonenfant, D; Cornille, K; Fritsch, C; Leroy, C; Ramos, P; Voshol, H	1
Bell, J; Cheng, SY; Eckerdt, F; Giles, FJ; Goldman, S; Iqbal, A; Lulla, RR; Nakano, I; Platanias, LC	1
Baxter, RC; Pavlakis, N; Smith, RC; Wong, MH; Xue, A	1
Carneiro, F; Carneiro, P; Fernandes, MS; Melo, S; Seruca, R; Velho, S	1
Antony, R; Baselga, J; Castel, P; Garraway, LA; Ghandi, M; Le, X; Luo, F; Razavi, P; Scaltriti, M; Treacy, DJ	1
Liu, P; Xu, B; Zhang, C	1
Fernandez-Marcos, PJ; Lopez-Guadamillas, E; Martinez, S; Muñoz-Martin, M; Pastor, J; Serrano, M	1
Bonazzi, VF; Cummings, MC; Geng, X; Ju, RJ; Mahon, CE; Packer, LM; Pollock, PM; Stephenson, SA	1
Baselga, J; Brook, S; Haimovitz-Friedman, A; Healey, JH; Heller, DA; Humm, JL; Mizrachi, A; Powell, SN; Rajasekhar, VK; Scaltriti, M; Shah, J; Shamay, Y; Soong, J	1
Avsar, E; Bendell, JC; Chatterjee, A; Delord, JP; Demuth, T; Elez, E; Eskens, FALM; Faris, JE; Jaeger, S; Lenz, HJ; Lolkema, MP; Maharry, K; Schellens, JHM; Schuler, M; Sharma, S; Spreafico, A; Tabernero, J; Tan, E; van Geel, RMJM; Wainberg, ZA; Yaeger, R; Yamada, Y; Yoshino, T	1
Chen, SM; Chen, Y; Ding, J; Geng, MY; Meng, LH; Sun, YM; Wang, X; Xu, YC; Yang, XY	1
Capitani, S; Celeghini, C; Evangelisti, C; Marisi, G; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Ulivi, P; Ultimo, S; Zauli, G	1
Banno, E; de Velasco, MA; Fujita, Y; Kamata, K; Kitano, M; Kudo, M; Mizukami, T; Nakamura, Y; Nishio, K; Sakai, K; Terashima, M; Togashi, Y	1
Hahn, WC; Sandoval, GJ	1
Camenisch, G; James, AD; Luneau, A; Marvalin, C; Meissner, A	1
Aristizabal Prada, ET; Auernhammer, CJ; Briest, F; Detjen, K; Exner, S; Fischer, C; Freitag, H; Grabowski, P; Grossman, A; Grötzinger, C; Lauseker, M; Möbs, M; Nölting, S; Rentsch, J; Schrader, J; Siegmund, B; Weissmann, V	1
Chen, B; Kraus, D; Palasuberniam, P	1
Chen, IC; Cheng, AL; Hsiao, LP; Huang, IW; Lin, CH; Lu, YS; Wei-Wu Chen, T; Yeh, LC; Yu, HC	1
Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A	1
Belen García, A; Blanco-Aparicio, C; Blasco, MA; Cortés, J; Gómez-Casero, E; Martínez, P; Martínez-Torrecuadrada, J; Méndez-Pertuz, M; Palafox, M; Pastor, J; Serra, V	1
Baselga, J; Berlin, J; Blumenstein, L; Bootle, D; Burris, HA; Coughlin, C; Demanse, D; Gil-Martin, M; Huang, A; Janku, F; Juric, D; Middleton, MR; Quadt, C; Rodon, J; Rugo, HS; Schellens, JHM; Schuler, M; Seggewiss-Bernhardt, R; Tabernero, J	1
Guan, J; Huang, D; Okret, S; Yakimchuk, K	1
Bergholz, JS; Roberts, TM; Zhao, JJ	1
Cojocaru, V; Del Rosario, RC; Jankowski, A; Jauch, R; Malik, V; Prabhakar, S; Srivastava, Y; Wang, X; Wei, Y	1
Cristofanilli, M; Gradishar, WJ; Helenowski, I; Jain, S; Rademaker, A; Santa-Maria, CA; Shah, AN; Siziopikou, K	1
Amiel, J; Berteloot, L; Blanc, E; Blanc, T; Boccara, O; Boddaert, N; Bole-Feysot, C; Broissand, C; Canaud, G; Chaussain, C; Cormier-Daire, V; Duong, JP; Grenier, N; Guibaud, L; Hoguin, C; Johnson, SC; Joly, D; Knebelmann, B; Ladraa, S; Laroche-Raynaud, C; Legendre, C; Lyonnet, S; Magassa, S; Martinez, F; Merville, P; Michot, C; Pannier, S; Picard, A; Rabia, SH; Sadoine, J; Sarnacki, S; Slimani, L; Soupre, V; Terzi, F; Venot, Q; Yamaguchi, J	1
Contreras, D; García-Escudero, R; Gutiérrez-Muñoz, C; Lorz, C; Navarro, EM; Paramio, JM; Segrelles, C	1
Auriemma, RS; Cappabianca, P; Cavallo, LM; Colao, A; De Martino, MC; Di Cera, M; Frio, F; Grasso, LFS; Patalano, R; Pivonello, C; Pivonello, R; Solari, D; Vitulli, F	1
Cheung, P; Kakit, C; Kiess, N; Parsons, R; Pegno, S; Poulikakos, PI; Schmidt, H; Stratikopoulos, EE; Szabolcs, M; Wu, X	1
Barrett, JW; Fung, K; Khan, MI; MacNeil, D; Mymryk, JS; Nichols, AC; Pinto, N; Ruicci, KM; Yoo, J	1
Arteaga, C; Floris, G; Hoste, G; Jongen, L; Matton, T; Menten, J; Neven, P; Punie, K; Slembrouck, L; Vanden Bempt, I; Vander Borght, S; Wildiers, H	1
Ahn, YO; Heo, DS; Keam, B; Kim, DW; Kim, M; Kim, S; Kim, TM	1
Cheng, H; Ding, J; Liu, C; Liu, P; Liu, Z; Luo, F; Sang, X; Shen, L; Wang, M; Wang, X; Xue, Y; Yi, J; Zhang, N; Zhang, Y; Zhao, W	1
Baselga, J; Blumenstein, L; Bootle, D; Burris, HA; Demanse, D; Gil-Martin, M; Huang, A; Janku, F; Juric, D; Mayer, IA; Middleton, MR; Quadt, C; Rodón, J; Rugo, HS; Schuler, M; Schumacher, K; Seggewiss-Bernhardt, R	1
Ando, Y; Iwasa, S; Kakizume, T; Natsume, K; Quadt, C; Saka, H; Suenaga, N; Takahashi, S; Yamada, Y	1
Badarni, M; Balaban, N; Cohen, L; Dinur, AB; Elkabets, M; Grénman, R; Joshua, BZ; Prasad, M; Rotblat, B; Yegodayev, KM; Zorea, J	1
Ledermann, JA	1
Aghajanian, C; Barry, WT; Birrer, M; Buss, MK; Cadoo, KA; Cantley, LC; Coleman, RL; Curtis, J; D'Andrea, AD; Eismann, J; Farooq, S; Kaufmann, SH; Kirschmeier, P; Kochupurakkal, B; Konstantinopoulos, PA; Liu, J; Luo, W; Matulonis, UA; Mayer, EL; Mills, GB; O'Cearbhaill, RE; Palakurthi, S; Shapiro, GI; Swisher, EM; Westin, SN; Whalen, C; Winer, E; Wulf, GM	1
Bargou, RC; Brünnert, D; Chatterjee, M; Driessen, C; Goyal, P; Heiden, R; Kirner, S; Kraus, M; Stühmer, T	1
Basu, R; Chen, X; McLean, BA; Oudit, GY; Patel, VB; Shah, S; Vanhaesebroeck, B; Wang, F; Zhabyeyev, P	1
André, F; Campone, M; Ciruelos, E; Conte, P; Hirawat, S; Inoue, K; Iwata, H; Juric, D; Kaufman, B; Loibl, S; Longin, AS; Lu, YS; Mayer, IA; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Wilke, C; Yamashita, T	1
Han, ES; Mortimer, J; Wen, W; Xing, Q; Yan, J; Yim, JH; Yost, SE; Yuan, Y	1
Hayashi, SI; Niwa, T; Tsuboi, K; Uematsu, C; Yamaguchi, Y	1
Sidaway, P	1
Stirrups, R	1
Alvarado, D; Duvvuri, U; Godse, NR; Grandis, JR; Hedberg, ML; Kemp, C; Khan, NI; Kim, S; Kulkarni, S; LaVallee, T; Meister, KS	1
Markham, A	1
Aristizabal Prada, ET; Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Eisenhofer, G; Fankhauser, M; Fassnacht, M; Favier, J; Gieldon, L; Goncalves, J; Grossman, AB; Klink, B; Knösel, T; Lauseker, M; Maurer, J; Nölting, S; Orth, M; Pacak, K; Rank, P; Reincke, M; Rubinstein, G; Spitzweg, C; Spöttl, G; William, D; Ziegler, CG	1
Delgado, C; Díaz, M; Lizarraga, R; López Gutiérrez, JC; Martínez Urrutia, MJ; Miguel, M; Triana, P	1
Gámez, B; Mishina, Y; Rosa, JL; Sánchez-de-Diego, C; Valer, JA; Ventura, F	1
Park, J; Shin, SW	1
Copur, MS; Jonglertham, P	1
André, F; Mills, D; Taran, T	1
Melegari, E; Palleschi, M; Rocca, A	1
Aschenbrenner, DS	1
Beauchamp, EM; Bell, JB; Blyth, GT; Clymer, J; Eckerdt, F; Goldman, S; Platanias, LC	1
Cao, P; Ding, D; Gu, J; Jiang, N; Li, S; Lin, L; Lv, Y; Ma, X; Wang, Y; Xiao, X; Zhong, L	1
Antoine, A; Baselga, J; Cantley, LC; Chandarlapaty, S; Chang, MT; Dickler, MN; Friedman, LS; Gorelick, A; Jhaveri, K; Johnson, JL; Kazmi, A; Ladewig, E; Lin, TY; Rabadan, R; Razavi, P; Reznik, E; Scaltriti, M; Schimmoller, F; Sebra, R; Shah, H; Shao, H; Smith, ML; Taylor, BS; Toska, E; Vasan, N; Wilson, TR; Xu, G	1
Adler, B; Bass, IR; Gallagher, EJ; Ryncarz, A; Tiersten, A; Trlica, K	1
Adamo, B; Brasó-Maristany, F; Chic, N; Conte, B; Galván, P; González-Farré, B; Martinez, A; Martínez, D; Martínez-Sáez, O; Muñoz, M; Pascual, T; Prat, A; Rodríguez, A; Rodríguez, AB; Sanfeliu, E; Schettini, F; Vidal, M	1
André, F; Campone, M; Cerda, H; Ciruelos, EM; Conte, P; Gaudenzi, F; Iwata, H; Jurado, JC; Juric, D; Loibl, S; Lteif, A; Mayer, I; Miller, M; Mills, D; Rugo, HS; Stemmer, SM; Toledano, I; Wilke, C; Yamashita, T	1
Bayley, A; Bratman, SV; Cho, J; Day, D; Giuliani, M; Hansen, AR; Hope, A; Jang, R; Karithanam, R; Kim, J; O'Sullivan, B; Prawira, A; Ringash, J; Siu, LL; Spreafico, A; Waldron, J; Weinreb, I	1
Copur, MS	1
Irurzun-Arana, I; McDonald, TO; Michor, F; Trocóniz, IF	1
Barrios, DM; Blinder, VS; Bromberg, JF; Drullinsky, PR; Funt, SA; Jhaveri, KL; Lacouture, ME; Lake, DE; Lyons, T; Modi, S; Razavi, P; Sidel, M; Traina, TA; Vahdat, LT; Wang, DG	1
Cui, H; Dai, X; Fang, X; Han, G; Mao, H; Sun, B; Wang, B; Zhou, S	1
Furukawa, K; Naruse, T; Okuyama, K; Omori, K; Tsuchihashi, H; Umeda, M; Yanamoto, S	1
Danzer, SC; Gross, C; MacLeod, MC; Tiwari, D; White, AR	1
Chang, YC; Chao, TY; Chen, SC; Chitapanarux, I; Gao, M; Jung, KH; Kim, JH; Lee, KS; Liu, CT; Lu, YS; Park, YH; Shotelersuk, K; Slader, C; Sohn, J; Tseng, LM; Valenti, R; Yang, Y	1
Cui, H; Dai, X; Fang, X; Han, G; Jiang, Y; Mao, H; Sun, B; Wang, B; Zhou, S	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Azad, AK; Eitzen, G; Moore, RB; Murray, AG; Oudit, GY; Vanhaesebroeck, B; Zhabyeyev, P	1
Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM	1
Berno, V; Berquez, M; Butler, R; Devuyst, O; Festa, BP; Gadsby, JR; Gallop, JL; Jackson, SP; Luciani, A	1
Marmé, F; Mavratzas, A	1
Corbaux, P; Sabatier, R	1
Hedges, CP; Hickey, AJR; Masson, SWC; Merry, TL; Pham, T; Shepherd, PR; Shetty, B	1
Ailles, L; Barrett, JW; Boutros, PC; Fung, K; Howlett, CJ; MacNeil, D; Meens, J; Mymryk, JS; Nichols, AC; Pinto, N; Plantinga, P; Ruicci, KM; Stecho, W; Yoo, J	1
Blumenstein, L; Gajewska, M; Heimbach, T; Kourentas, A; Lorenzo, S; Mueller-Zsigmondy, M; Sinn, A; Velinova, M	1
Clark, AS; DeMichele, A; Makhlin, I	1
Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Chatterjee, DK; Chen, W; Chen, X; Fan, J; Fernandes, LL; Gao, JJ; Geiser, G; Ghosh, S; Goldberg, KB; Gong, Y; Jiang, X; King-Kallimanis, BL; Kluetz, PG; Li, E; Narayan, P; Pathak, A; Pazdur, R; Philip, R; Prowell, TM; Qiu, J; Reyes Turcu, F; Rhieu, SY; Ricks, TK; Seidman, J; Song, P; Tang, S; Theoret, MR; Wang, X; Windsor, K; Yu, J; Zhang, X	1
Bernards, R; Boelens, MC; Huijberts, SCFA; Opdam, FL	1
André, F; Campone, M; Ciruelos, EM; Conte, PF; Ghaznawi, F; Inoue, K; Iwata, H; Juric, D; Kaper, M; Kaufman, B; Loibl, S; Lu, YS; Mayer, IA; Miller, M; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Yamashita, T	1
Foukakis, T; Matikas, A	1
Bell, JB; Eckerdt, FD; Fischietti, M; Goldman, S; Gonzalez, C; Mazewski, C; Nakano, I; Oh, MS; Perez, RE; Platanias, LC	1
Jian, L; Lian, S; Liu, M; Liu, N; Wang, S; Zhang, G; Zhang, Y; Zhao, Q	1
Geum, D; Han, DG; Kim, JM; Seo, SW; Yoon, IS; Yun, H	1
Garneau, AP; Haydock, L; Isenring, P; Tremblay, LE	1
Lambertini, M; Punie, K	1
Chen, JH; Chuang, FC; Hwang, TZ; Su, YC; Wang, CC; Yeh, SA	1
Dalianis, T; Herold, N; Holzhauser, S; Kostopoulou, ON; Lukoseviciute, M; Papachristofi, C; Vasilopoulou, C; Wickström, M	1
Boix, J; Hedges, CP; Jaiswal, JK; Merry, TL; Shepherd, PR; Shetty, B	1
Almodallal, Y; Cook, K; Jatoi, A; Martin, N	1
Arce, C; Bachelot, T; Chia, S; Ciruelos, E; Drullinsky, P; Hsu, WC; Juric, D; Kanakamedala, H; Lerebours, F; Neven, P; Park, YH; Prat, A; Rugo, HS; Ruiz-Borrego, M; Shen, YM; Sophos, N; Turner, N; Turner, S; Zarate, JP	1
Ali, T; Bergamaschi, D; Boehm, K; Celik, S; El Hasnaouy, M; Harwood, CA; Kafaei Golahmadi, D; Kaffa, A; Leigh, IM; Lyu, Y; Maffucci, T; Mannella, V; Mirza, AN	1
Chandiwana, D; Chia, S; Hsu, WC; Kanakamedala, H; Park, J; Ridolfi, A; Rugo, HS; Turner, S; Yu, CL; Zarate, JP	1
Chandarlapaty, S; Drago, JZ; Fornier, MN; Iasonos, A; Jhaveri, K; Modi, S; Pareja, F; Patil, S; Ratzon, F; Rosen, N; Shah, PD; Sklarin, NT; Wang, R	1
Ajipa, O; Andre, F; Beck, JT; Blumenstein, L; Curigliano, G; Donnet, V; Fazio, N; Hubner, RA; Jhaveri, K; Lahner, H; Li, Z; Martin, M; Maur, M; Tortora, G	1
Bièche, I; Chateau-Joubert, S; Dahmani, A; De Plater, L; El Botty, R; Jacquemetton, J; Kassem, L; Le Romancer, M; Marangoni, E; Montaudon, E; Morisset, L; Poulard, C; Sourd, L; Trédan, O; Treilleux, I; Vacher, S	1
Athikari, N; Datar, R; Khandare, H; Kumar, P; Limaye, S; Madre, C; Peshattiwar, V; Pragya, R; Sambath, J; Sheth, H; Shreenivas, A	1
Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J	1
Almodallal, Y; Cook, KD; Jatoi, A; Lammert, LM; Le-Rademacher, JG; Lee, M; Singh, AB; Yadav, S	1
Albert, R; Alcon, C; Baselga, J; Gómez Tejeda Zañudo, J; Johnson, GN; Kowalski, K; Letai, A; Mao, P; Montero, J; Scaltriti, M; Wagle, N; Xu, G	1
Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N	1
Balbin, A; Cresta, S; Crystal, A; Curigliano, G; De Vita, S; Duhoux, FP; He, W; Huober, J; Jhaveri, K; Ji, Y; Juric, D; Kundamal, N; Layman, RM; Sheng, Q; Takahashi, S; Terret, C; Yap, YS	1
Asnafi, V; Bayard, C; Boccara, O; Bonnotte, B; Broissand, C; Canaud, G; Cassaca, R; Chapelle, C; Chopinet, C; Delestre, F; Duong, JP; Fraissenon, A; Fraitag, S; Guibaud, L; Hoguin, C; Kaltenbach, S; Ladraa, S; Legendre, C; Magassa, S; Mirault, T; Morin, G; Soupre, V; Venot, Q; Villarese, P; Yamaguchi, J; Zerbib, L	1
Calvisi, DF; Chen, K; Chen, X; Evert, M; Li, B; Shang, R; Song, X; Xu, H; Zhang, Y; Zhong, S	1
Cao, ZR; Chen, Y; Chen, ZQ; Ding, J; Meng, LH; Wang, Y; Wang, YX; Xu, L; Yang, CH; Zhang, X	1
Hart, JR; Liu, X; Vogt, PK; Wang, MW; Xia, T; Xu, Y; Yang, D; Yang, S; Zhang, H; Zhang, Y; Zhou, Q; Zou, X	1
Balic, M; Bartsch, R; Dandachi, N; Gerritsmann, H; Graf, R; Heitzer, E; Jahn, S; Jost, PJ; Kashofer, K; Klocker, EV; Lindenmann, J; Posch, F; Regitnig, P; Suppan, C; Terbuch, A; Zhou, Q	1
Barbash, Z; Bauman, JE; Cho, J; Grandis, JR; Jin, N; Johnson, DE; Jura, N; Kang, H; Keam, B; Kim, HR; Kim, MO; Krogan, NJ; Lee, MJ; Li, H; Mills, GB; Ng, PK; Swaney, DL; Tarcic, G; Torosyan, H; VanLandingham, NK; Zeng, Y	1
Chen, C; Chen, X; Chi, L; Guo, X; Guo, Z; He, J; Liang, J; Wei, L; Ye, X; Zheng, Y	1
Cheung, YM; Cromwell, GE; McDonnell, ME; Min, L; Tolaney, SM	1
Aapro, MS; Goncalves, MD; Lacouture, ME; Masharani, U; O'Shaughnessy, JA; Rugo, HS	1
Alesandrini, M; Aubert, H; Blanc, T; Boddaert, N; Boutry, N; Branle, F; Broissand, C; Canaud, G; Catteau, B; Chapelle, C; Degrugillier-Chopinet, C; Domanski, O; Dubos, F; Fraissenon, A; Guibaud, L; Han, TK; Herbreteau, G; Hoguin, C; Mezel, A; Morin, G; Petit, F; Sarnacki, S; Vincent, M	1
Agim, NG; Fernandes, NJ; Kolitz, E; Ludwigl, K	1
Garreta Fontelles, G; Grande Moreillo, C; Pardo Pastor, J	1
Adalsteinsson, V; Batalini, F; Cantley, LC; D'Andrea, A; Eismann, J; Konstantinopoulos, PA; Matulonis, UA; Mayer, EL; Polak, M; Shapiro, GI; Swisher, EM; Tayob, N; Winer, EP; Wulf, GM; Xiong, N	1
Arranz Martin, A; Ballesteros García, A; Marazuela Azpiroz, M; Pla Peris, B; Sebastián-Valles, F	1
Azakami, D; Ishioka, K; Kinoshita, N; Maeda, M; Michishita, M; Morimatsu, M; Ochiai, K; Onozawa, E; Sadahira, T; Sakai, H; Sakaue, M; Tanaka, Y; Watanabe, M; Yamamoto, M	1
Bini, M; Bogani, G; Chiappa, V; Conca, E; Indini, A; Raspagliesi, F; Ronzulli, D	1
Jacobson, A	1
Adam, V; Bedard, PL; Carrasco, E; Criscitiello, C; Di Leo, A; Pérez-Fidalgo, JA; Regan, MM; Ribi, K	1
Bauer, S; Berhanu, G; Brandt, U; Gelderblom, H; Grignani, G; Heinrich, MC; Italiano, A; Pantaleo, MA; Reichardt, P; Reyners, AKL; Schöffski, P; Stark, D; Stefanelli, T; Valverde, C	1
Amadou, C; Balla, V; Chafai, K; Ezenfis, J; Oumbiche, H; Penfornis, A	1
Blackley, EF; Bujak, AZ; Callahan, J; Dawson, SJ; Francis, PA; Ftouni, S; Hicks, RJ; Ko, YA; Lee, CK; Lo, LL; Loi, S; Luen, SJ; Moodie, K; Savas, P; Silva, MJ; van Geelen, CT; Wein, L; Weng, CF; Yeung, MM	1
Arap, W; Bansal, P; Bischoff, J; Bocklage, TJ; Dobroff, AS; Ganesan, S; Groisberg, R; Gutenkunst, RN; Mannakee, BK; Masterson, M; Ness, SA; Pasqualini, R; Rabinowitz, I; Riedlinger, GM; Shaheen, MF; Smith, TL; Sokol, ES; Tarleton, CA; Tse, JY	1
Dao, EA; George, SJ; Heberton, MM; Kovitz, CA; Pacha, O; Patel, AB; Phillips, RM	1
Alessandrini, G; Blandino, G; Botti, C; Carosi, M; Ciliberto, G; Cioce, M; Daralioti, T; Di Martino, S; Donzelli, S; Fazio, VM; Goeman, F; Orlandi, G; Piccolo, S; Sacconi, A; Strano, S; Telera, S; Zanconato, F	1
Dubois, J; Facundo, GB; Gavra, P; Kleiber, N; Lapointe, C; Remy, A; Théorêt, Y; Tran, TH; Winikoff, R	1
Baertschiger, RM; Coblentz, A; Cohen-Gogo, S; Gupta, AA; Kanwar, N; Malkin, D; Morgenstern, DA; Putra, J; Shaikh, F; Shlien, A; Villani, A	1
Diness, BR; Frevert, S; Harder, KM; Hjortshøj, TD; Hove, H; Jørgensen, FS; Karstensen, HG; Schönewolf-Greulich, B	1
Dores, GM; Jones, SC; Nayernama, A; Osgood, C; Pradhan, SM; Prowell, TM; Sullivan, KM	1
Bennett, JT; Bindschadler, M; Bly, RA; Bonilla-Velez, J; Bull, C; Dahl, JP; Dmyterko, V; Drusin, M; Friedman, SD; Ganti, S; Jensen, DM; Kong, A; Lutsky, E; Mercan, E; Perkins, JA; Perkins, JN; Shivaram, GM; Wenger, TL; Zenner, K	1
Choi, IH; Choi, JM; Choi, Y; Do, HS; Heo, SH; Jang, JH; Kim, YM; Lee, BH; Lee, Y; Yoo, HW; Yum, MS	1
Behbod, F; Bu, W; Ibrahim, AA; Jiang, W; Ku, AT; Li, Y; Lin, M; McCue, BL; Miles, G; Nagi, C; Williams, LC; Young, AIJ	1
Kaderbhaï, CG; Royer, B; Schmitt, A	1
Huang, Z; Li, J; Lou, C; Ye, Y; Zhang, M; Zhang, Y	1
Cahn, A; Fischer, M; Leibowitz, G; Levenberg, S; Riahi, Y; Shoyhet-Smoilovsky, H; Zick, A	1

Reviews

9 review(s) available for thiazoles and byl719

Article	Year
Alpelisib: First Global Approval. Drugs, 2019, Volume: 79, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Female; Fulvestrant; Humans; Male; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Thiazoles; United States; United States Food and Drug Administration	2019
Alpelisib to treat breast cancer. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:6 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Fulvestrant; Humans; Mutation; Receptor, ErbB-2; Thiazoles	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Alpelisib in the treatment of metastatic HR+ breast cancer with Future oncology (London, England), 2021, Volume: 17, Issue:1 Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Mutation; Neoadjuvant Therapy; Progression-Free Survival; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Thiazoles	2021
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis. BioMed research international, 2020, Volume: 2020 Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Morpholines; Mutation; Network Meta-Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Signal Transduction; Thiazoles; Treatment Outcome	2020
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting. Breast cancer research and treatment, 2021, Volume: 188, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mutation; Thiazoles	2021
A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast (Edinburgh, Scotland), 2022, Volume: 61 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Phosphatidylinositol 3-Kinases; Thiazoles	2022
Pharmacokinetics and Pharmacodynamic of Alpelisib. Clinical pharmacokinetics, 2023, Volume: 62, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles	2023
Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 159 Topics: Antineoplastic Agents; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Thiazoles	2023

Trials

26 trial(s) available for thiazoles and byl719

Article	Year
Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. British journal of clinical pharmacology, 2014, Volume: 78, Issue:3 Topics: Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Nonlinear Dynamics; Phosphoinositide-3 Kinase Inhibitors; Thiazoles; Tissue Distribution	2014
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic Cancer discovery, 2017, Volume: 7, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Thiazoles	2017
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-01, Volume: 36, Issue:13 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Thiazoles; Treatment Outcome	2018
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast cancer research and treatment, 2018, Volume: 171, Issue:2 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Maytansine; Middle Aged; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Retreatment; Taxoids; Thiazoles; Trastuzumab; Treatment Outcome	2018
Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 2018, Volume: 558, Issue:7711 Topics: Adult; Animals; Child; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Female; Heart Failure; HeLa Cells; Humans; Lipoma; Male; Mice; Molecular Targeted Therapy; Musculoskeletal Abnormalities; Nevus; Phenotype; Scoliosis; Sirolimus; Syndrome; Thiazoles; Vascular Malformations; Vascular Neoplasms	2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA oncology, 2019, 02-01, Volume: 5, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Receptors, Estrogen; Thiazoles; Time Factors	2019
Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer science, 2019, Volume: 110, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Asian People; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Protein Kinase Inhibitors; Thiazoles; Young Adult	2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology, 2019, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genome, Human; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles; Treatment Outcome	2019
Alpelisib for The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Diarrhea; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles	2019
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles	2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral oncology, 2020, Volume: 108 Topics: Aged; Chemoradiotherapy; Cisplatin; Female; Humans; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Thiazoles	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection. The AAPS journal, 2020, 10-18, Volume: 22, Issue:6 Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Caco-2 Cells; Cross-Over Studies; Dogs; Drug Evaluation, Preclinical; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Models, Biological; Permeability; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rats; Solubility; Tablets; Therapeutic Equivalency; Thiazoles; Young Adult	2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 04-01, Volume: 27, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Drug Approval; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Reported Outcome Measures; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles	2021
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles	2021
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. The oncologist, 2021, Volume: 26 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Receptor, ErbB-2; Thiazoles	2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology, 2021, Volume: 22, Issue:4 Topics: Adolescent; Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles	2021
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. The oncologist, 2021, Volume: 26, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles	2021
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-15, Volume: 27, Issue:14 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Receptor, ErbB-2; Thiazoles; Trastuzumab	2021
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European journal of cancer (Oxford, England : 1990), 2021, Volume: 151 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Europe; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thiazoles; Treatment Outcome; United States	2021
Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer. The oncologist, 2021, Volume: 26 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Thiazoles	2021
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Female; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles; Triple Negative Breast Neoplasms	2022
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ Future oncology (London, England), 2022, Volume: 18, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Trastuzumab	2022
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. BMC cancer, 2022, May-06, Volume: 22, Issue:1 Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Thiazoles; Treatment Outcome	2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer discovery, 2022, 09-02, Volume: 12, Issue:9 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mutation; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles; Triple Negative Breast Neoplasms	2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an eLife, 2022, 07-05, Volume: 11 Topics: Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Endothelial Cells; Genomics; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; Lymphangioma; Lymphatic Abnormalities; Membrane Proteins; Mutation; Sequence Analysis, DNA; Thiazoles	2022

Other Studies

134 other study(ies) available for thiazoles and byl719

Article	Year
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13 Topics: Animals; Biological Availability; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Female; Humans; Mice; Models, Molecular; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles	2013
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Molecular cancer therapeutics, 2014, Volume: 13, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Silencing; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyrroles; Quinazolines; RNA Interference; Signal Transduction; Thiazoles; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays	2014
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Molecular cancer therapeutics, 2014, Volume: 13, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Mice; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Rats; Thiazoles; Xenograft Model Antitumor Assays	2014
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer research, 2014, Jun-15, Volume: 74, Issue:12 Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays	2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International journal of cancer, 2015, Feb-15, Volume: 136, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Male; Mice, Inbred C57BL; Mice, Nude; Osteoblasts; Osteoclasts; Osteosarcoma; Phosphoinositide-3 Kinase Inhibitors; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Investigational new drugs, 2015, Volume: 33, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature, 2015, Feb-12, Volume: 518, Issue:7538 Topics: Alleles; Animals; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Loss of Heterozygosity; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Thiazoles; Xenograft Model Antitumor Assays	2015
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer discovery, 2015, Volume: 5, Issue:2 Topics: Animals; Carbamates; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melanoma; Melanoma, Experimental; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Random Allocation; Sulfonamides; Thiazoles	2015
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Chromones; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Signal Transduction; Thiazoles	2015
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Transplantation; ortho-Aminobenzoates; Pyrimidinones; Receptor, ErbB-2; Signal Transduction; Thiazoles	2015
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer research, 2015, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Quinazolinones; Thiazoles	2015
Breaking up is hard to do: PI3K isoforms on the rebound. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromones; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Neoplasms; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidinones; Thiazoles	2015
Drug combo beneficial in colorectal cancer. Cancer discovery, 2015, Volume: 5, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Sulfonamides; Thiazoles	2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase. Oncotarget, 2015, Apr-10, Volume: 6, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Enzyme Inhibitors; Humans; Imidazoles; Leukemia, Myeloid, Acute; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triazines; U937 Cells	2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer cell, 2015, Apr-13, Volume: 27, Issue:4 Topics: Animals; Antibodies, Monoclonal, Humanized; Axl Receptor Tyrosine Kinase; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine, 2015, Apr-15, Volume: 7, Issue:283 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; Mutation; Neoplasm Metastasis; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Research Design; Signal Transduction; Thiazoles	2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Molecular cancer therapeutics, 2015, Volume: 14, Issue:8 Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays	2015
Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Biotransformation; Carbon Radioisotopes; Enzyme Inhibitors; Feces; Follow-Up Studies; Half-Life; Humans; Hydrolysis; Intestinal Absorption; Intestinal Elimination; Male; Metabolic Clearance Rate; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Renal Elimination; Thiazoles; Tissue Distribution; Urine; Young Adult	2015
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene, 2016, 07-07, Volume: 35, Issue:27 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice, Knockout; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays	2016
HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, Nov-10, Volume: 112, Issue:45 Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles	2015
Somatic Activating PIK3CA Mutations Cause Venous Malformation. American journal of human genetics, 2015, Dec-03, Volume: 97, Issue:6 Topics: Alleles; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation; Gene Frequency; Genetic Association Studies; High-Throughput Nucleotide Sequencing; Human Umbilical Vein Endothelial Cells; Humans; Mutation; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, TIE-2; Signal Transduction; Thiazoles; Transfection; Vascular Malformations; Veins	2015
Long-Term Evaluation of MEK Inhibitor Retinal Toxicity With Multimodal Imaging. Ophthalmic surgery, lasers & imaging retina, 2016, Volume: 47, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Female; Fluorescein Angiography; Follow-Up Studies; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Multimodal Imaging; Optical Imaging; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Retina; Retinal Detachment; Thiazoles; Tomography, Optical Coherence	2016
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition. Breast cancer research : BCR, 2016, Apr-05, Volume: 18, Issue:1 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Somatomedin; Thiazoles; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2016
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Glioma; Humans; Imidazoles; Molecular Targeted Therapy; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Signal Transduction; Thiazoles; Thiazolidines	2016
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Flavonoids; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Thiazoles; TOR Serine-Threonine Kinases	2016
Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. Oncotarget, 2016, Oct-18, Volume: 7, Issue:42 Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; HCT116 Cells; Humans; Mutation; Proto-Oncogene Proteins p21(ras); RNA Interference; Signal Transduction; Thiazoles	2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer discovery, 2016, Volume: 6, Issue:10 Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Thiazoles; Up-Regulation	2016
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11 Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays	2016
PI3Kα inhibition reduces obesity in mice. Aging, 2016, 11-04, Volume: 8, Issue:11 Topics: Animals; Body Weight; Energy Metabolism; Male; Mice; Obesity; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Thiazoles; Treatment Outcome	2016
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Molecular cancer therapeutics, 2017, Volume: 16, Issue:4 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Morpholines; Mutation; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Sulfonamides; Thiazoles; Xenograft Model Antitumor Assays	2017
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature communications, 2017, 02-13, Volume: 8 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Protein Kinase Inhibitors; Thiazoles; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer. Theranostics, 2017, Volume: 7, Issue:4 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Drug Resistance; Female; Gene Expression Profiling; Heterografts; Humans; Mice, SCID; Protein-Tyrosine Kinases; Thiazoles; Treatment Failure	2017
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, Apr-04, Volume: 8, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoenzymes; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Thiazoles; Triazines	2017
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International journal of oncology, 2017, Volume: 50, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Thiazoles	2017
Going beyond genetics to discover cancer targets. Genome biology, 2017, 05-22, Volume: 18, Issue:1 Topics: Animals; Antineoplastic Agents; Atlases as Topic; Breast Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Mice; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays	2017
Comparison of Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:8 Topics: Carbon Radioisotopes; Chromatography, Liquid; Fluorine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Thiazoles	2017
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PloS one, 2017, Volume: 12, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Chromogranin A; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Humans; Pancreas; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Somatostatin; Signal Transduction; Thiazoles	2017
Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy. Molecular cancer therapeutics, 2017, Volume: 16, Issue:11 Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Humans; Imidazoles; Mice; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Verteporfin; Xenograft Model Antitumor Assays	2017
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Scientific reports, 2017, 08-29, Volume: 7, Issue:1 Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Tamoxifen; Thiazoles	2017
Survival of pancreatic cancer cells lacking KRAS function. Nature communications, 2017, 10-23, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles	2017
Modulation of telomere protection by the PI3K/AKT pathway. Nature communications, 2017, 11-02, Volume: 8, Issue:1 Topics: Aging; Animals; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA Damage; Humans; Mice; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Stability; Proto-Oncogene Proteins c-akt; Telomere; Telomeric Repeat Binding Protein 1; Thiazoles	2017
The PI3Kα Inhibitor Alpelisib Has Activity in Cancer discovery, 2018, Volume: 8, Issue:4 Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Thiazoles	2018
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma. Molecular cancer therapeutics, 2018, Volume: 17, Issue:5 Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Humans; Interleukin Receptor Common gamma Subunit; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Piperidines; Pyrazoles; Pyrimidines; Stromal Cells; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays	2018
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-01, Volume: 36, Issue:13 Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Neoplasms; Phosphatidylinositol 3-Kinase; Protein Isoforms; Thiazoles	2018
DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1. Nucleic acids research, 2018, 06-20, Volume: 46, Issue:11 Topics: Cell Line, Tumor; Chromatin; Dimerization; DNA; Enhancer Elements, Genetic; Gene Expression Regulation; HCT116 Cells; Hepatocyte Nuclear Factor 3-alpha; Humans; Inverted Repeat Sequences; MCF-7 Cells; Phosphoinositide-3 Kinase Inhibitors; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Thiazoles	2018
Bosutinib Inhibits EGFR Activation in Head and Neck Cancer. International journal of molecular sciences, 2018, 06-21, Volume: 19, Issue:7 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Mice; Mice, Nude; Nitriles; Proto-Oncogene Proteins c-abl; Quinolines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays	2018
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine, 2018, Volume: 62, Issue:3 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Everolimus; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Rats; Signal Transduction; Thiazoles	2018
Mouse ER+/PIK3CA Oncogene, 2019, Volume: 38, Issue:1 Topics: Aniline Compounds; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cocarcinogenesis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Mutation, Missense; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neuropeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Thiazoles	2019
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. Oral oncology, 2018, Volume: 84 Topics: Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Genes, ras; Head and Neck Neoplasms; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Molecular Targeted Therapy; Mutation, Missense; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Ribosomal Protein S6 Kinases; RNA Interference; Squamous Cell Carcinoma of Head and Neck; Thiazoles; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein	2018
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Clinical drug investigation, 2018, Volume: 38, Issue:11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Middle Aged; Mutation; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles	2018
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer research and treatment, 2019, Volume: 51, Issue:3 Topics: Afatinib; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Amplification; Humans; Imidazoles; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Sequence Analysis, RNA; Thiazoles; Triazines	2019
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. Cancer letters, 2019, Volume: 440-441 Topics: Animals; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Estrogen Receptor alpha; Female; G2 Phase; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice; Mice, Nude; Nuclear Proteins; Thiazoles; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays	2019
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI insight, 2019, 03-12, Volume: 5 Topics: Animals; Anthracenes; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Squamous Cell Carcinoma of Head and Neck; Thiazoles; Tongue; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Xenograft Model Antitumor Assays	2019
Extending the scope of PARP inhibitors in ovarian cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:4 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles	2019
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Biochimica et biophysica acta. Molecular basis of disease, 2019, 06-01, Volume: 1865, Issue:6 Topics: A549 Cells; Amino Acid Substitution; Antineoplastic Agents; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression; Glycine; Histone Deacetylases; Humans; Indoles; Models, Biological; Multiple Myeloma; Mutation; Oligopeptides; Panobinostat; Phosphatidylinositol 3-Kinase; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrimidines; Thiazoles	2019
PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction. Journal of the American Heart Association, 2019, 05-07, Volume: 8, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Atrophy; Class I Phosphatidylinositol 3-Kinases; Doxorubicin; Female; Heart; Mice; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Thiazoles; Ventricular Dysfunction, Right; Ventricular Remodeling	2019
Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Scientific reports, 2019, 05-17, Volume: 9, Issue:1 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2019
Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer. Breast cancer (Tokyo, Japan), 2019, Volume: 26, Issue:6 Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Thiazoles; Transfection; Tumor Microenvironment	2019
Alpelisib effective in advanced-stage disease. Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:8 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Humans; Thiazoles	2019
Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:7 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Fulvestrant; Humans; Mutation; Thiazoles	2019
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Scientific reports, 2019, 06-24, Volume: 9, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Mice; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays	2019
Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 11-01, Volume: 160, Issue:11 Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line; Drug Screening Assays, Antitumor; Drug Synergism; Everolimus; Female; Humans; Male; Mice; Middle Aged; Pheochromocytoma; Primary Cell Culture; Signal Transduction; Thiazoles	2019
Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome. Journal of pediatric and adolescent gynecology, 2019, Volume: 32, Issue:6 Topics: Adolescent; Class I Phosphatidylinositol 3-Kinases; Female; Genitalia, Female; Humans; Lipoma; Musculoskeletal Abnormalities; Nevus; Protein Kinase Inhibitors; Thiazoles; Vascular Malformations	2019
Inhibition of phosphatidylinositol 3-kinase α (PI3Kα) prevents heterotopic ossification. EMBO molecular medicine, 2019, Volume: 11, Issue:9 Topics: Activin Receptors, Type I; Activins; Animals; Bone Morphogenetic Proteins; Class I Phosphatidylinositol 3-Kinases; Humans; Mice; Ossification, Heterotopic; Phosphoinositide-3 Kinase Inhibitors; Thiazoles	2019
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. The New England journal of medicine, 2019, 08-15, Volume: 381, Issue:7 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Humans; Thiazoles	2019
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. The New England journal of medicine, 2019, 08-15, Volume: 381, Issue:7 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Humans; Thiazoles	2019
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply. The New England journal of medicine, 2019, 08-15, Volume: 381, Issue:7 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Humans; Thiazoles	2019
Precision medicine: PI3K targeting in advanced breast cancer. Breast cancer research and treatment, 2019, Volume: 178, Issue:2 Topics: Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Mutation; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; PTEN Phosphohydrolase; Thiazoles	2019
New Drug for Breast Cancer with Specific Genetic Mutations. The American journal of nursing, 2019, Volume: 119, Issue:9 Topics: Adult; Breast Neoplasms; Female; Humans; Middle Aged; Mutation; Thiazoles	2019
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma. Scientific reports, 2019, 09-06, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Imidazoles; Medulloblastoma; Mice, Nude; Protein Kinase Inhibitors; Sarcoma, Ewing; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1	2019
PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673. Oncology reports, 2019, Volume: 42, Issue:5 Topics: Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Middle Aged; Phosphatidylinositol 3-Kinases; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Thiazoles; Uterine Cervical Neoplasms	2019
Double Science (New York, N.Y.), 2019, 11-08, Volume: 366, Issue:6466 Topics: Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Female; Humans; Mutation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Domains; Thiazoles	2019
Novel breast cancer treatment leads to hyperglycaemia. Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:5 Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Blood Glucose Self-Monitoring; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Hyperglycemia; Monitoring, Ambulatory; Phosphoinositide-3 Kinase Inhibitors; Prediabetic State; Thiazoles	2020
Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast cancer research : BCR, 2020, 05-13, Volume: 22, Issue:1 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Databases, Genetic; Disease-Free Survival; Female; Genetic Testing; Humans; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Thiazoles	2020
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. Cancer research, 2020, 08-15, Volume: 80, Issue:16 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinolines; Software; Thiazoles; Triple Negative Breast Neoplasms	2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast cancer research and treatment, 2020, Volume: 183, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Eruptions; Eosinophilia; Exanthema; Female; Histamine Antagonists; Humans; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Thiazoles	2020
Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly. Cell death & disease, 2020, 07-06, Volume: 11, Issue:7 Topics: Biomarkers; Cell Differentiation; Cell Proliferation; Cell Shape; Class I Phosphatidylinositol 3-Kinases; Fingers; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Limb Deformities, Congenital; Mesenchymal Stem Cells; Mutation; Osteoblasts; Osteogenesis; Signal Transduction; Thiazoles; Transcription Factors	2020
Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma. Oncology reports, 2020, Volume: 44, Issue:3 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chemoradiotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neoplasm Invasiveness; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Thiazoles; Xenograft Model Antitumor Assays	2020
PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes. Neurobiology of disease, 2020, Volume: 144 Topics: Adenine; Animals; Cerebral Cortex; Class I Phosphatidylinositol 3-Kinases; Epilepsy; Female; Hippocampus; Male; Megalencephaly; Mice; Neurons; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Seizures; Thiazoles	2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Tamoxifen; Thiazoles	2021
Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1. Cell death & disease, 2020, 07-30, Volume: 11, Issue:7 Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Cell Differentiation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; E2F1 Transcription Factor; Female; Fingers; Gain of Function Mutation; Gene Knockdown Techniques; Humans; Hypertrophy; Limb Deformities, Congenital; Mice, Nude; Mutation; Stem Cells; Thiazoles; Up-Regulation	2020
Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth. Oncogene, 2020, Volume: 39, Issue:41 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Kidney Neoplasms; Melanoma, Experimental; Mice, Knockout; Microvessels; Morpholines; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidinones; Sunitinib; Thiazoles; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2	2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles	2021
The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease. Kidney international, 2020, Volume: 98, Issue:4 Topics: Actins; Dent Disease; Humans; Mice; Oculocerebrorenal Syndrome; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Thiazoles	2020
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation]. Bulletin du cancer, 2020, Volume: 107, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles	2020
Prolonged treatment with a PI3K p110α inhibitor causes sex- and tissue-dependent changes in antioxidant content, but does not affect mitochondrial function. Bioscience reports, 2020, 10-30, Volume: 40, Issue:10 Topics: Administration, Oral; Aging; Animals; Catalase; Cell Line; Class I Phosphatidylinositol 3-Kinases; Female; Glutathione; Hydrogen Peroxide; Liver; Longevity; Male; Mice; Mitochondria; Models, Animal; Muscle, Skeletal; NF-E2-Related Factor 2; Oxidation-Reduction; Sex Factors; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Time Factors; Up-Regulation	2020
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma. Journal of experimental & clinical cancer research : CR, 2020, Oct-15, Volume: 39, Issue:1 Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mice; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance? Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2 Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Tamoxifen; Thiazoles	2021
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. British journal of cancer, 2021, Volume: 124, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Cetuximab; Cohort Studies; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Thiazoles	2021
SOLAR1s: alpelisib returns to earth? Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:2 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Fulvestrant; Humans; Thiazoles	2021
Combined PI3Kα-mTOR Targeting of Glioma Stem Cells. Scientific reports, 2020, 12-14, Volume: 10, Issue:1 Topics: Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Spheroids, Cellular; Thiazoles; TOR Serine-Threonine Kinases	2020
A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Jan-15, Volume: 1163 Topics: Animals; Chromatography, High Pressure Liquid; Limit of Detection; Male; Nonlinear Dynamics; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Thiazoles	2021
Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America. Journal of molecular medicine (Berlin, Germany), 2021, Volume: 99, Issue:3 Topics: Abdominal Pain; Adult; Canada; Class I Phosphatidylinositol 3-Kinases; Female; Gain of Function Mutation; Humans; Hypertrophy; Leg; Lipomatosis; Mesentery; Mutation, Missense; Point Mutation; Port-Wine Stain; Protein Kinase Inhibitors; Thiazoles; Veins	2021
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib. ESMO open, 2021, Volume: 6, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Thiazoles	2021
Continuing Advancements in Breast Cancer Care. Oncology (Williston Park, N.Y.), 2021, Jan-11, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Humans; Medical Oncology; Paclitaxel; Thiazoles	2021
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy. PloS one, 2021, Volume: 16, Issue:1 Topics: Aminopyridines; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; Humans; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Radiation-Sensitizing Agents; Thiazoles	2021
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. International journal of oncology, 2021, Volume: 58, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cisplatin; Cytostatic Agents; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Neuroblastoma; Phosphoinositide-3 Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Thiazoles; Vincristine	2021
Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet. Biomolecules, 2021, 01-25, Volume: 11, Issue:2 Topics: Aging; Animals; Behavior, Animal; Class I Phosphatidylinositol 3-Kinases; Female; Glucose; Glucose Tolerance Test; Homeostasis; Liver; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Muscles; Phosphatidylinositol 3-Kinases; Receptor, Insulin; Thiazoles	2021
Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings. Journal of geriatric oncology, 2021, Volume: 12, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Hyperglycemia; Thiazoles	2021
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors. International journal of molecular sciences, 2021, Mar-30, Volume: 22, Issue:7 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chromones; Humans; Imidazoles; Isoenzymes; Keratinocytes; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Skin Neoplasms; Thiazoles; Thiazolidinediones; TOR Serine-Threonine Kinases	2021
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. Breast cancer research : BCR, 2021, 05-21, Volume: 23, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Proto-Oncogene Proteins pp60(c-src); Receptors, Estrogen; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays	2021
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report. JCO precision oncology, 2021, Volume: 5 Topics: Anilides; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Nitriles; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Thiazoles; Tosyl Compounds	2021
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. International journal of molecular sciences, 2021, May-14, Volume: 22, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Cell Line-Specific Network Models of ER Cancer research, 2021, 09-01, Volume: 81, Issue:17 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Computer Simulation; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Models, Theoretical; Myeloid Cell Leukemia Sequence 1 Protein; Receptors, Estrogen; Retinoblastoma Binding Proteins; Signal Transduction; Thiazoles; Ubiquitin-Protein Ligases	2021
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells, 2021, 07-02, Volume: 10, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes	2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21 Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptors, Estrogen; Thiazoles; Thiophenes	2021
Alpelisib administration reduced lymphatic malformations in a mouse model and in patients. Science translational medicine, 2021, Oct-06, Volume: 13, Issue:614 Topics: Animals; Humans; Mice; Thiazoles	2021
Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell death & disease, 2021, 10-08, Volume: 12, Issue:10 Topics: Anilides; Animals; Benzoxazoles; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Female; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Thiazoles; Treatment Outcome; Tumor Burden	2021
Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. Cancer letters, 2022, 01-01, Volume: 524 Topics: Acetanilides; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Histone Acetyltransferases; Humans; Lymphoma, B-Cell; Mice; Morpholines; Nerve Tissue Proteins; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-myc; Pyrroles; Receptors, Cell Surface; Thiazoles; Xenograft Model Antitumor Assays	2022
Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 11-09, Volume: 118, Issue:45 Topics: Animals; Class Ia Phosphatidylinositol 3-Kinase; Cryoelectron Microscopy; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Sf9 Cells; Spodoptera; Thiazoles	2021
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. British journal of cancer, 2022, Volume: 126, Issue:3 Topics: Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Estrogen Receptor alpha; Female; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Mutation; Neoplasm Metastasis; Receptors, Progesterone; Thiazoles	2022
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. The Journal of clinical investigation, 2021, 11-15, Volume: 131, Issue:22 Topics: Animals; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Male; Mice; Middle Aged; Mutation; Protein Domains; Squamous Cell Carcinoma of Head and Neck; Thiazoles	2021
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. British journal of clinical pharmacology, 2022, Volume: 88, Issue:5 Topics: Adverse Drug Reaction Reporting Systems; Breast Neoplasms; Databases, Factual; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Hyperglycemia; Pharmacovigilance; Thiazoles; World Health Organization	2022
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast cancer research and treatment, 2022, Volume: 192, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Triple Negative Breast Neoplasms	2022
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. The Journal of experimental medicine, 2022, 03-07, Volume: 219, Issue:3 Topics: Biomarkers; Class I Phosphatidylinositol 3-Kinases; Diagnostic Imaging; Disease Management; Disease Susceptibility; Female; Growth Disorders; Humans; Infant; Male; Phenotype; Thiazoles; Treatment Outcome	2022
Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders. Journal of pediatric hematology/oncology, 2022, 11-01, Volume: 44, Issue:8 Topics: Child; Class I Phosphatidylinositol 3-Kinases; Humans; Mutation; Quality of Life; Thiazoles	2022
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. British journal of clinical pharmacology, 2022, Volume: 88, Issue:8 Topics: Catalytic Domain; Class I Phosphatidylinositol 3-Kinases; Growth Disorders; Humans; Lipoma; Musculoskeletal Abnormalities; Mutation; Nevus; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Syndrome; Thiazoles; Vascular Malformations	2022
Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations. Frontiers in endocrinology, 2022, Volume: 13 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Humans; Phosphatidylinositol 3-Kinases; Thiazoles	2022
Oncology reports, 2022, Volume: 47, Issue:4 Topics: Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dogs; HeLa Cells; Hemangiosarcoma; Humans; Mutation; Thiazoles	2022
BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer. Tumori, 2023, Volume: 109, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Neoplasm Recurrence, Local; Thiazoles; Uterine Cervical Neoplasms	2023
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. The oncologist, 2022, 03-28, Volume: 27, Issue:Suppl 1 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Thiazoles	2022
An atypical alpelisib-induced hyperglycemic hyperosmolar and diabetic ketoacidosis state: A case report and critical analysis of alpelisib-induced hyperglycemia management guidelines. Annales d'endocrinologie, 2022, Volume: 83, Issue:4 Topics: Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Hyperglycemia; Thiazoles	2022
Periorbital edema associated with alpelisib. Cancer treatment and research communications, 2022, Volume: 32 Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Edema; Exanthema; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles	2022
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. Molecular cancer, 2022, 07-22, Volume: 21, Issue:1 Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mutation; Organoids; Thiazoles	2022
Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data. Pediatric blood & cancer, 2022, Volume: 69, Issue:10 Topics: Antineoplastic Agents; Blood Coagulation Disorders; Child; Drug Repositioning; Humans; Quality of Life; Thiazoles; Vascular Malformations	2022
Response to Alpelisib in an Adolescent With JCO precision oncology, 2022, Volume: 6 Topics: Adolescent; Class I Phosphatidylinositol 3-Kinases; Gastrointestinal Stromal Tumors; Humans; Thiazoles	2022
Early diagnosis enabling precision medicine treatment in a young boy with PIK3R1-related overgrowth. European journal of medical genetics, 2022, Volume: 65, Issue:10 Topics: Child; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Early Diagnosis; Female; Humans; Male; Musculoskeletal Abnormalities; Mutation; Precision Medicine; Pregnancy; Syndrome; Thiazoles; Transcription Factors; Vascular Malformations	2022
Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration. JAMA oncology, 2022, 10-01, Volume: 8, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Humans; Thiazoles; United States; United States Food and Drug Administration	2022
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth. Genetics in medicine : official journal of the American College of Medical Genetics, 2022, Volume: 24, Issue:11 Topics: Child; Class I Phosphatidylinositol 3-Kinases; Humans; Mutation; Phosphatidylinositol 3-Kinases; Thiazoles	2022
Clinical and genetic analyses of patients with lateralized overgrowth. BMC medical genomics, 2022, 09-30, Volume: 15, Issue:1 Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Magnetic Resonance Imaging; Mutation; Propranolol; Proto-Oncogene Proteins p21(ras); Thiazoles; Whole Body Imaging	2022
Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer prevention research (Philadelphia, Pa.), 2023, 02-06, Volume: 16, Issue:2 Topics: Animals; Class I Phosphatidylinositol 3-Kinases; Estrogen Receptor Modulators; Female; Hyperplasia; Mice; Phosphoinositide-3 Kinase Inhibitors; Precancerous Conditions; Thiazoles	2023
Alpelisib (Vijoice) for PIK3CA-related overgrowth spectrum. The Medical letter on drugs and therapeutics, 2022, 11-14, Volume: 64, Issue:1663 Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Thiazoles	2022
Alpelisib in Intractable Non-Islet-Cell Tumor Hypoglycemia. The New England journal of medicine, 2023, May-18, Volume: 388, Issue:20 Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Hypoglycemia; Paraneoplastic Syndromes; Thiazoles	2023